Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07518784 · ClinicalTrials.gov registry record
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
A clinical trial, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 26
- Enrollment target
NCT07518784: Recruiting study, sponsored by University of California, San Diego.
NCT07518784 is a clinical trial that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07518784 is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 26 participants
- Enrollment target
Study Summary
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use. In this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations. Study participants will be asked to complete a one-time visit which includes: * LiverScope exam * MR exam * FibroScan exam (optional) * Blood draw * Completion of study questionnaires
Primary Outcome
Assessment of agreement between LiverScope® measurements and conventional MR measurements in the liver.
Interventions
- DIAGNOSTIC_TEST Blood draw
- OTHER Questionnaire
- DIAGNOSTIC_TEST MR exam
- OTHER Body measurements
- DIAGNOSTIC_TEST LiverScope® exam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2026-06-30 |
What NCT07518784 shows while recruiting
NCT07518784 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT07518784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07518784 about?
NCT07518784 is a clinical study titled "Accurate Point of Care Liver Disease Diagnostics (Phase 2)". This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, i...
What is the current status of trial NCT07518784?
This trial is currently recruiting. The enrollment target is 26 participants. The study started on 2026-04-08. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT07518784?
The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST), Questionnaire (OTHER), MR exam (DIAGNOSTIC_TEST), Body measurements (OTHER), LiverScope® exam (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07518784?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI